Group 1 - The stock price of Te Yi Pharmaceutical reached 9.28 yuan as of the close on August 15, 2025, with an increase of 0.10 yuan, representing a rise of 1.09% [1] - The trading volume on that day was 153,060 hands, with a transaction amount of 1.41 billion yuan [1] - Te Yi Pharmaceutical operates in the pharmaceutical manufacturing industry, primarily engaged in the research, production, and sales of traditional Chinese medicine, chemical preparations, chemical raw materials, and chemical products [1] Group 2 - In the revenue composition for 2024, the pharmaceutical industry accounted for 97.65% of the company's total revenue [1] - On the evening of August 15, Te Yi Pharmaceutical announced that its sixth board of directors' second meeting approved a proposal to use part of the idle raised funds from the 2023 fiscal year for cash management and to temporarily supplement working capital [1]

Group 1 - Tianjin Tasly Pharmaceutical announced the convening of its 12th meeting of the 9th Board of Directors on August 14, 2025, to review the "2025 Semi-Annual Report" and other documents [1] - For the year 2024, the revenue composition of Tasly is as follows: Traditional Chinese Medicine accounts for 70.89%, Chemical Preparations 15.38%, Pharmaceutical Commerce 10.53%, Biological Drugs 2.25%, and Chemical Raw Materials 0.61% [1] - As of the report date, Tasly's market capitalization is 24.2 billion yuan [1] Group 2 - Huakang Co., Ltd. is facing uncertainty regarding an 11 billion yuan acquisition, as the major client of the acquisition target has been in debt crisis for two years, raising questions about its ability to contribute significant revenue [1]

Group 1 - The revenue composition of North China Pharmaceutical for the year 2024 is as follows: chemical preparations account for 44.02%, chemical raw materials account for 26.72%, biological preparations account for 16.36%, pharmaceutical intermediates account for 6.23%, and pharmaceutical and other logistics trade account for 4.61% [1] Group 2 - As of the announcement date, the total external guarantees provided by North China Pharmaceutical and its subsidiaries amount to approximately 1.757 billion yuan, which represents 32.6% of the audited net assets attributable to ordinary shareholders for the year 2024 [3] - The company has provided guarantees totaling approximately 1.667 billion yuan for its subsidiaries, accounting for 30.93% of the audited net assets attributable to ordinary shareholders for the year 2024 [3] - The amount of guarantees provided to entities outside the consolidated financial statements is 90 million yuan, which is 1.67% of the audited net assets attributable to ordinary shareholders for the year 2024 [3]

关于公司 2025 年第一季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所《上市公司行业信息披露指引第六号——医药制造》及《关 于做好主板上市公司 2025 年第一季度报告披露工作的重要提醒》的要求，现将公 司 2025 年第一季度主要经营数据披露如下： 一、报告期内分行业经营数据 证券代码：600535 证券简称：天士力 编号：临 2025-040 号 天士力医药集团股份有限公司 1 单位：元 币种：人民币 行业 主营业务收入 主营业务成本 毛利率（%） 2025 年 1 季度 2024 年 1 季度 增长 率（%） 2025 年 1 季度 2024 年 1 季度 增长 率（%） 2025 年 1 季度 2024 年 1 季度 增长 率 医药 工业 1,841,853,945.50 1,808,711,593.51 1.83 544,797,151.33 507,143,805.22 7.42 70.42 71.96 -1.54 医药 商业 201,533,271.02 226 ...